Amphastar Pharmaceuticals (AMPH) reported $183.11 million in revenue for the quarter ended December 2025, representing a year-over-year decline of 1.8%. EPS of $0.73 for the same period compares to $0.92 a year ago.
The reported revenue represents a surprise of -5.63% over the Zacks Consensus Estimate of $194.03 million. With the consensus EPS estimate being $0.97, the EPS surprise was -24.49%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Amphastar performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net revenues- BAQSIMI: $46.71 million versus the two-analyst average estimate of $52.07 million. The reported number represents a year-over-year change of +11.8%.
- Net revenues- Primatene MIST: $27.93 million versus $31.48 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -3.5% change.
- Net revenues- Lidocaine: $14.9 million versus $13.51 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +3.5% change.
- Net revenues- Epinephrine: $17.09 million versus the two-analyst average estimate of $19.78 million. The reported number represents a year-over-year change of -8.6%.
- Net revenues- Glucagon: $14.08 million versus the two-analyst average estimate of $10.59 million. The reported number represents a year-over-year change of -45%.
View all Key Company Metrics for Amphastar here>>>
Shares of Amphastar have returned +7.1% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amphastar Pharmaceuticals, Inc. (AMPH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
